Skip to main content
Premium Trial:

Request an Annual Quote

AGRF, Garvan Institute Partner to Give Australian Researchers Access to HiSeq X Ten Sequencers

NEW YORK (GenomeWeb) – The Australian Genome Research Facility and the Garvan Institute of Medical Research have partnered to give Australian genomics researchers easier access to Garvan's Illumina HiSeq X Ten platform for human whole-genome sequencing, the institutions said today.

Under the agreement, AGRF will facilitate access to human whole-genome sequencing services on the HiSeq X Ten through the Garvan Institute starting Oct. 1.

The Garvan Institute is one of the first customers of the HiSeq X Ten, a set of 10 high-throughput sequencers that Illumina launched earlier this year. The instruments, which allow researchers to sequence more than 350 human genomes per week, are located at the Garvan's Kinghorn Centre for Clinical Genomics.

"Providing access to the best suite of relevant technologies is one of AGRF’s key remits as a national genomics provider. As such we are excited to be able to partner with the Garvan Institute to offer the capabilities of the HiSeq X Ten to Australia," said AGRF CEO Sue Forrest in a statement.

AGRF, founded as a joint venture between the University of Queensland and the Walter and Eliza Hall Institute of Medical Research, is a non-profit organization that facilitates researchers' access to genomic technologies through a national network of services and locally available expertise.

The Garvan Institute conducts medical research in a variety of areas. Two years ago, the institute established a facility for clinical-grade genome sequencing and large-scale research projects.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.